30th week of 2015 patent applcation highlights part 7 |
Patent application number | Title | Published |
20150202143 | SYSTEM, METHOD, AND KIT FOR SELECTING AND PREPARING CUSTOMIZED COSMETICS - A kit for preparing a customized cosmetic includes at least one of five cosmetic bases. Each of the five cosmetic bases correspond to at least one of a plurality of primary categories. The kit additionally includes at least one cosmetic active ingredient for admixing with the at least one cosmetic base. The at least one cosmetic active ingredient corresponds to at least one of the plurality of primary categories or at least one of the plurality of secondary categories. | 2015-07-23 |
20150202144 | Water Activated Shaving Wipe - A solvent activated shaving wipe includes a substrate, such as a cloth having a generally porous construction. The shaving wipe includes a dehydrated shaving cream composition applied or impregnated into the substrate that is dry from the point of manufacturing, packaging, and distribution. The shaving cream composition includes stearic acid, lanolin, glycerin, polyoxyethylene, sorbitan monostearate, but specifically does not include a solvent. | 2015-07-23 |
20150202145 | SUNSCREEN COMPOSITION WITH IMPROVED AESTHETIC PROPERTIES - Sunscreen compositions having an SPF of 30 to 50 which include mixtures of zinc oxide and titanium dioxide, cross linked silicone-containing compounds and anti-oxidants to provide protection against UVA and UVB. | 2015-07-23 |
20150202146 | Paxillin Stimulating Compositions and Cosmetic Uses Thereof - Cosmetic compositions comprising one or more paxillin stimulators and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The paxillin stimulators and combinations thereof are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging. | 2015-07-23 |
20150202147 | Modified Release Formulations Of A Bupropion Salt - The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition. | 2015-07-23 |
20150202148 | DRY POWDER INHALERS COMPRISING A CARRIER OTHER THAN LACTOSE - This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them. | 2015-07-23 |
20150202149 | PHARMACEUTICAL COMPOSITIONS OF MESALAMINE SUPPOSITORIES - The present invention relates to pharmaceutical compositions of mesalamine suppositories. In particular, the invention relates to pharmaceutical suppositories comprising mesalamine or salts thereof and at least two oily or fatty bases. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of ulcerative colitis or ulcerative proctitis. | 2015-07-23 |
20150202150 | Topical Drug Delivery System for Ophthalmic Use - Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v. | 2015-07-23 |
20150202151 | ENCAPSULATION SYSTEM - The invention pertains to an encapsulation system; in particular a 3-phase system comprising an inner, second and outer phase wherein the second phase is gaseous, and wherein the 3-phase system has a lifetime of at least 3 min and the second phase has a diameter of less than 1 mm. An example of such a system is a stable, small antibubble. Also, the invention pertains to methods of making such 3-phase systems, and to use and methods of use thereof. In particular, 3-phase systems according to the invention are stabilized by surface active particles or molecules, such as for instance colloidal particles. The 3-phase systems of the invention can include a variety of other compounds, and can among others be used in pharmaceutical- or food-based applications. In particular, a 3-phase system according to the invention, such as for example an antibubble, may deliver pharmaceutical compounds. | 2015-07-23 |
20150202152 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT - The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer. | 2015-07-23 |
20150202153 | LIPOSOMAL DRUG DELIVERY SYSTEM - The invention relates to a drug delivery system, particularly to a liposomal drug delivery system. Most particularly the invention relates to a liposomal drug delivery system for the release of at least one drug compound at a target site within a human or animal body. The invention extends to a method of manufacturing the drug delivery system. | 2015-07-23 |
20150202154 | LIPID MEMBRANE STRUCTURE HAVING INTRANUCLEAR MIGRATING PROPERTY - A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell. | 2015-07-23 |
20150202155 | CROSS-LINKED POLYMER PARTICLES - Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed. | 2015-07-23 |
20150202156 | DRY POWDER PHARMACEUTICAL COMPOSITION, ITS PREPARATION PROCESS AND STABLE AQUEOUS SUSPENSION OBTAINED FROM SUCH COMPOSITION - Pharmaceutical composition in a dry powder form comprising at least one hydrophobic active principle, at least one water-soluble excipient and at least one surfactant, wherein the particles in said dry powder state have a Volume Mean Diameter VMD | 2015-07-23 |
20150202157 | COMPOSITIONS AND METHODS FOR ENHANCING NEURONAL PHOSPHORYLATION HOMEOSTASIS, AND MODULATING DYSFUNCTIONAL EXOCYTOSIS AND NEUROTRANSMITTER RELEASE - Provided are methods for treating pre-neuronal loss abnormalities in synaptic function, comprising administrating to a subject having neurons, an ionic aqueous solution comprising charge-stabilized oxygen-containing nanostructures having an average diameter of less than 100 nm in an amount and for a time period sufficient for preventing or reducing abnormalities in synaptic function that precede neuronal loss and/or NFTs formation in taupathies. Also provided are methods for treating pre-neuronal loss abnormalities in synaptic function, comprising contacting neurons in vitro or ex vivo with an ionic aqueous solution comprising charge-stabilized oxygen-containing nanostructures having an average diameter of less than 100 nm in an amount and for a time period sufficient for preventing or reducing abnormalities in synaptic function that precede neuronal loss and/or NFTs formation. | 2015-07-23 |
20150202158 | GASTRO-RETENTIVE DRUG DELIVERY SYSTEM - The invention relates to floating drug delivery systems(FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore,allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive. | 2015-07-23 |
20150202159 | PROCESS FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION - Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation. | 2015-07-23 |
20150202160 | IMMEDIATE RELEASE FILM COATINGS CONTAINING MEDIUM CHAIN GLYCERIDES AND SUBSTRATES COATED THEREWITH - The present invention is directed to immediate release film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain medium chain glycerides as detackifiers. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is polyvinyl alcohol and the medium chain glycerides are mixtures of caprylic (8 carbon chain) and capric (10 carbon chain) mono- and diesters of glycerin. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed. | 2015-07-23 |
20150202161 | PROCESS FOR MANUFACTURING DRUG DELIVERY FORMULATIONS - The present invention provides for methods of producing a drug product that is capable of providing controlled and sustained release of a drug. Particularly, the release of the drug will be to a specific tissue area in the body. The methods include, but are not limited to, providing an impermeable casing with an open end, placing a compressed drug pellet into the impermeable casing, coating the open end of the impermeable casing with a permeable layer to create a release window for the drug product to provide controlled and/or sustained release of the drug. | 2015-07-23 |
20150202162 | COLONIC DRUG DELIVERY FORMULATION - A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon. | 2015-07-23 |
20150202163 | POLYMER-POLYMER COMPOSITE NANOASSEMBLIES AND APPLICATIONS THEREOF - The invention provides novel nanoscale delivery vehicles and composite nanoassemblies built from distinct nanoassembly units (e.g., block copolymer micelles and nanogels) with stoichiometric control. These intelligent composite nanoassemblies independently retain the key features of the nanoassembly units and greatly expand the potential functional features attainable based on the surface functionalization. The invention provides a novel approach to constructing nano-vehicles with controllable morphology based on combination of cooperative releasing mechanisms (e.g., redox sensitive nanogels and pH sensitive micelles). Two kinds of guests can be seperately and stably encapsulated in the composite nanocontainers, and then released sequentially under the stimulation of pH change and reduced glutathione. | 2015-07-23 |
20150202164 | Oral Rapamycin Nanoparticle Preparations - Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc. | 2015-07-23 |
20150202165 | USE OF POLYUNSATURATED KETONES FOR THE TREATMENT OF PSORIASIS - Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C | 2015-07-23 |
20150202166 | METHODS FOR MAINTAINING OR IMPROVING HEALTH, WELL-BEING AND/OR A PHYSIOLOGICAL FUNCTION IN A SUBJECT - The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. | 2015-07-23 |
20150202167 | Trans-Clomiphene Formulations and Uses Thereof - The present invention provides iraws-clomiphene and pharmaceutically acceptable salts and solvates thereof, characterized in that trans-clomiphene is in particulate form having a specific size range. The invention is also directed to pharmaceutical compositions comprising or formulated using trans-clomiphene or pharmaceutically acceptable salts and solvates having a specified size range and their use in treating disorders including secondary hypogonadism, type 2 diabetes, elevated cholesterol, elevated triglycerides, wasting, lipodystrophy, female and male infertility, benign prostate hypertrophy, prostate cancer, breast cancer, ovarian cancer and endometrial cancer. | 2015-07-23 |
20150202168 | ORAL FILM FORMULATIONS COMPRISING DAPOXETINE AND TADALAFIL - The present invention relates to a formulation comprising the combination of dapoxetine or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof. The present invention further relates to a process for preparing this formulation and to the use thereof in the treatment of the premature ejaculation related to erectile dysfunction. | 2015-07-23 |
20150202169 | NOVEL REGULATORS OF ALDEHYDE DEHYDROGENASE ALDH3A1 AND RELATED THERAPEUTIC METHODS - Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to cancer chemotherapeutic agents that are degraded by ALD3H1. The compositions described herein act as competitive inhibitors of ALD3H1 and thereby reduce breakdown of chemotherapeutics by this enzyme, and increase their efficacy for cancer treatment. | 2015-07-23 |
20150202170 | IMMUNE CELL ACTIVATION INHIBITOR AND USE THEREOF - The present invention provides a pharmaceutical that can be used widely for intractable neurological diseases, inflammatory diseases, etc. The immune cell activation inhibitor of the present invention contains bromovalerylurea or a derivative thereof. The immune cell activation inhibitor of the present invention can be used as a pharmaceutical for, for example: chronic neurological diseases such as Parkinson's disease and Alzheimer's disease; acute neurological diseases such as cerebral infarction and brain injury; and inflammatory diseases such as systemic inflammatory response syndromes. | 2015-07-23 |
20150202171 | PATCH - A patch comprising a support layer and an adhesive layer, wherein the adhesive layer comprises diclofenac sodium, dimethyl sulfoxide, and citric acid; a mass ratio between the diclofenac sodium and the citric acid (mass of diclofenac sodium:mass of citric acid) is 1:0.15 to 1:0.45; and a mass ratio between the diclofenac sodium and the dimethyl sulfoxide (mass of diclofenac sodium:mass of dimethyl sulfoxide) is 1:0.75 to 1:3. | 2015-07-23 |
20150202172 | NOVEL METHOD OF USE - The present invention is directed to methods of treating elderly patients with Alitretinoin severe chronic hand eczema (CHE), refractory to treatment with potent topical corticosteroids. One embodiment of the invention is a method of improving the efficacy of Alitretinoin treatment for Severe Refractory Chronic Hand Eczema (CHE) comprising
| 2015-07-23 |
20150202173 | METHOD FOR TREATING TRIPLE-NEGATIVE BREAST CANCER USING AMPI-109 - A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer. | 2015-07-23 |
20150202174 | RETINOIDS AND USE THEREOF - The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders. | 2015-07-23 |
20150202175 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation - The present document describes transdermal compositions comprising effective amounts of a nitric oxide amino acid ester compound, a skin penetration enhancer is association with a pharmaceutically acceptable carrier. Also described are methods of use for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, including peripheral vascular diseases. | 2015-07-23 |
20150202176 | Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis - The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) | 2015-07-23 |
20150202177 | Compositions and methods of use of phorbol esters in the treatment of neoplasms - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases. | 2015-07-23 |
20150202178 | Compositions and methods of use of phorbol esters - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects. | 2015-07-23 |
20150202179 | FATTY ACID DERIVATIVES FOR USE IN A METHOD OF TREATING DEPRESSION AND ASSOCIATED CONDITIONS - The invention provides fatty acid derivatives for use in a method of treatment of at least one disease, disorder or condition selected from anxiety, depression, conditions associated menopause, stress, bipolar disorder, neuropathic pain and fibromyalgia. | 2015-07-23 |
20150202180 | Pharmaceutical compositions of Anisomelic acid and the use thereof - A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided. | 2015-07-23 |
20150202181 | Method of and compounds for the reduction of alcoholic hangover - One embodiment of a composition containing 1200 mg of N-acetyl-L-cysteine and 400 mg of alpha-lipoic acid. For the purpose of eliminating many or all the symptoms of alcoholic hangover and the alcohol flushing reaction in susceptible individuals, this composition is ingested within 30 minutes prior to the initiation of drinking one or more alcoholic beverages and the same composition is ingested within 30 minutes after cessation of drinking alcoholic beverages. | 2015-07-23 |
20150202182 | METHOD FOR ADMINISTRATION - There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels. | 2015-07-23 |
20150202183 | PATCH - In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent. | 2015-07-23 |
20150202184 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 2015-07-23 |
20150202185 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS - The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds. | 2015-07-23 |
20150202186 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN - Described herein are methods for treating chemotherapy-induced peripheral neuropathy, or human immunodeficiency virus-associated sensory neuropathy, or symptoms thereof, comprising administering to an individual in need thereof a therapeutically effective amount of a cystathionine-γ-lyase (CSE) inhibitor. Also described herein are methods for using such CSE inhibitors in combination with other compounds. | 2015-07-23 |
20150202187 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating hypomelanotic conditions such as vitiligo and promoting melanogenesis. | 2015-07-23 |
20150202188 | RIFAXIMIN CRYSTALLINE FORMS AND METHODS OF PREPARATION THEREOF - The present invention is directed to methods for preparation of a composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β. For example, practice of a method of the invention can provide the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β wherein the rifaximin β is present in about 3-12% (w/w) or is present in about 5-8% (w/w). The composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β is prepared by dissolving raw rifaximin in a water-soluble organic solvent, for example ethanol, at reflux, then adding water to achieve a final mixed solvent of about 7:3 (v/v) solvent to water ratio, then cooling to 35-40° C. until crystallization commences, then further cooling with stirring to 0° C., then recovery of the crystallized material, and drying to a water content of between 2.5% and 5.0%, to provide the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β. The composition is suitable for medicinal use, such as in treatment of infections of the gastrointestinal tract. | 2015-07-23 |
20150202189 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY - Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof. | 2015-07-23 |
20150202190 | Otamixaban for Use in the Treatment of Non-ST Elevation Acute Coronary Syndrome in Patients Planned to Undergo Coronary Artery Bypass Grafting - The invention relates to otamixaban or a pharmaceutically acceptable salt thereof for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting. | 2015-07-23 |
20150202191 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2015-07-23 |
20150202192 | PHARMACEUTICAL COMPOSITION FOR TREATING GASTRO-OESOPHAGEAL REFLUX DISEASE - The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of | 2015-07-23 |
20150202193 | METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer. | 2015-07-23 |
20150202194 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 2015-07-23 |
20150202195 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION - Methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivinis is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. | 2015-07-23 |
20150202196 | Methods of Using C-Met Modulators - Disclosed are methods of treating cancer by administering a compound of Formula I, | 2015-07-23 |
20150202197 | Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase - The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: | 2015-07-23 |
20150202198 | Novel Cabergoline Derivatives - Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT | 2015-07-23 |
20150202199 | TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT - The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists. | 2015-07-23 |
20150202201 | CONCENTRATED, INHALABLE ANTIBIOTIC FORMULATION - A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions. | 2015-07-23 |
20150202202 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 2015-07-23 |
20150202203 | Method of Treating Gastrointestinal Stromal Tumors - The present invention relates to a method of treating gastrointestinal stromal tumors (GIST), especially GIST, which is progressing after imatinib therapy or after imatinib and sunitinib therapy, using a combination comprising (a) a c-kit inhibitor and (b) a dual KIT inhibitor and FGFR inhibitor or FGFR inhibitor. | 2015-07-23 |
20150202204 | METHOD FOR TREATING TAU PROTEIN-MEDIATED DEGENERATIVE NEURONAL DISEASE - Provided is a therapeutic agent for a degenerative neuronal disease, and more particularly, a composition containing, as an active ingredient, an inhibitor of anaplastic lymphoma kinase (ALK) activity of expression for treating a degenerative neuronal disease caused by aggregation and phosphorylation of tau protein. | 2015-07-23 |
20150202205 | AMINOPYRIMIDINE KINASE INHIBITORS - Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. | 2015-07-23 |
20150202206 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY - Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof. | 2015-07-23 |
20150202207 | PATCHES, FORMULATIONS, AND ASSOCIATED METHODS FOR TRANSDERMAL DELIVERY OF DRUGS - The present invention is drawn to transdermal drug formulations, transdermal patches incorporating such formulations, as well as associated methods. The formulations can include about 0.3 wt % to about 5 wt % of a drug, such as risperidone, about 4 wt % to about 30 wt % water, about 10 wt % to about 40 wt % glycerol, about 0.5 wt % to about 6 wt % oleyl alcohol. Other co-solvents and/or additives can be present to achieve a 100 wt % formulation. | 2015-07-23 |
20150202208 | ANTIVIRAL AGENT - The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity. | 2015-07-23 |
20150202209 | METHOD OF ENHANCING THE PERFORMANCE OF BROILER CHICKENS - A method of enhancing the performance of chicken comprising administering zilpaterol to the chicken wherein the concentration of zilpaterol is from about 1 ppm to about 13 ppm and is administered every day for a period of about 7 to about 21 days. | 2015-07-23 |
20150202210 | PHARMACEUTICAL COMPOSITION - The invention relates to a solid pharmaceutical composition comprising solid amorphous fulvestrant, said composition being formulated in combination with a solubilizing composition. The invention also relates to a method for preparing said composition and a kit including the composition. | 2015-07-23 |
20150202211 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE - This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount. | 2015-07-23 |
20150202212 | METHODS FOR IDENTIFYING AGENTS FOR TREATING SMOOTH MUSCLE DISORDERS AND COMPOSITIONS THEREOF - The invention generally relates to methods and compositions for identifying novel therapeutic agents, and uses thereof. More particularly, the invention relates to novel methods for identifying agents useful in treating smooth muscle disorders. | 2015-07-23 |
20150202213 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2015-07-23 |
20150202214 | COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATING CANCER - The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals. | 2015-07-23 |
20150202215 | METHOD OF TREATING AND PREVENTING BRAIN IMPAIRMENT USING Na+-K+-2Cl- COTRANSPORTER ISOFORM 1 INHIBITORS - The disclosure relates to a method of treating and/or preventing brain impairment in a subject that has or is susceptible to ammonia neurotoxicity (increased plasma ammonia), by administering a Na-; —K+-2CI- cotransporter isoform 1 (“NKCC1”) inhibitor to the selected subject under conditions effective to treat and/or prevent brain impairment. The disclosure further relates to methods of maintaining the fundamental function of astrocytic potassium buffering and inhibiting accumulation of potassium star rounding astrocytes, both of which involve contacting astrocytes with a NKCC 1 inhibitor. | 2015-07-23 |
20150202216 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES - The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent. | 2015-07-23 |
20150202217 | USE OF AN AMPHOTERIC CHELATING AGENT FOR PREVENTING CONTACT ALLERGIES - A method of preventing contact allergies includes using at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c′Dc with B being OH | 2015-07-23 |
20150202218 | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections - Disclosed are methods of treating, inhibiting, or preventing a viral infection in a mammal in need thereof by administering a therapeutically or prophylactically effective amount of an inhibitor of FAP, an inhibitor of DPPIV, an inhibitor of DPP8, or an inhibitor of DPP9. The inhibitor may act as both an inhibitor of DPPIV and an inhibitor of DPP8/9. The viral infection includes, but is not limited to, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, Polio virus, Coxsackie A virus, Coxsackie B virus, Rhino virus, respiratory syncytial virus, dengue virus, equine infectious anemia virus, Echo virus, small pox virus, Ebola virus, and West Nile virus. | 2015-07-23 |
20150202219 | NEUROPROTECTION FROM BRAIN ANOXIA AND REPERFUSION INJURY DURING STROKE AND COMPOSITIONS OF PKG PATHWAY ACTIVATORS AND METHOD OF USE THEREOF - A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway. | 2015-07-23 |
20150202220 | AGENTS, METHODS, AND DEVICES FOR AFFECTING NERVE FUNCTION - Agents, methods, and devices for affecting nerve function are described. One embodiment of an agent includes a cardiac glycoside, an ACE inhibitor, and an NSAID. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One embodiment of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing. | 2015-07-23 |
20150202221 | COMBINATION THERAPY FOR ACNE VULGARIS COMPRISING ADMINISTRATION OF ADAPALENE 0.3% GEL AND CLINDAMYCIN/BENZOYL PEROXIDE GEL - A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®. | 2015-07-23 |
20150202222 | TREATMENT OF SPINAL CORD INJURY OR TRAUMATIC BRAIN INJURY BY INHIBITION OF AMYLOIDOGENIC PROTEINS AND SYNUCLEIN PROTEIN ACCUMULATION OR AGGREGATION - Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions. | 2015-07-23 |
20150202223 | METHODS RELATING TO DNA-SENSING PATHWAY RELATED CONDITIONS - The invention provides, inter alia, methods for modulating DNA sensing pathways and the innate immune responses downstream of such pathways. The invention contemplates methods for down-regulating this pathway and/or the downstream innate immune response. The invention further contemplates methods for up-regulating this pathway and/or the downstream innate immune response. | 2015-07-23 |
20150202224 | METHOD OF TREATING IRON DEFICIENCY ANEMIA - Methods for predicting responsiveness of a subject to iron therapy and treatment methods related thereto. Such methods can be useful with respect to conditions, disorders, or diseases associated with iron deficiency anemia. | 2015-07-23 |
20150202225 | ANTI-REGURGITATION AND/OR ANTI-GASTROOESOPHAGEAL REFLUX COMPOSITION, PREPARATION AND USES - The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described. | 2015-07-23 |
20150202226 | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them - In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described. | 2015-07-23 |
20150202227 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE - The present invention relates to respirable dry powders that contain respirable dry particles that comprise calcium lactate, sodium chloride, leucine, and one or more additional therapeutic agents; wherein the ratio of calcium cation to sodium cation is about 4:1 (mole:mole); and, wherein the calcium lactate is about 45.0% (w/w) to about 58.6% (w/w), and the sodium chloride is about 1.9% (w/w) to about 3.9% (w/w), where all weights are on a dry basis. | 2015-07-23 |
20150202228 | SLEEP-IMPROVING AGENT, NON-REM SLEEP TIME-INCREASING AGENT, AND SEDATIVE AGENT - A sleep-improving agent, a non-REM sleep time-increasing agent, and a sedative agent, each of which includes a lipid-soluble antioxidant and a divalent metal as active ingredients. | 2015-07-23 |
20150202229 | Method for Inducing Immune Stimulation Using Non-Proliferative Allogeneic Leukocytes - This invention relates to cellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population capable of proliferating. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided. | 2015-07-23 |
20150202230 | LAT ADAPTER MOLECULE FOR ENHANCED T-CELL SIGNALING AND METHOD OF USE - LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods. | 2015-07-23 |
20150202231 | Modulation of the Immune Response - Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient. | 2015-07-23 |
20150202232 | EXPANSION OF HAEMOPOIETIC PRECURSORS - The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence of a population of cells enriched for STRO-1 | 2015-07-23 |
20150202233 | METHOD TO GENERATE TISSUE-ENGINEERED CARTILAGE IN ULTRASONIC BIOREACTORS - The present disclosure describes methods of using ultrasound to engineer cartilage, as well as a bioreactor that includes at least one ultrasound transducer. | 2015-07-23 |
20150202234 | Injectable Brown Adipose Microtissues for Treatment and Prevention of Obesity and Diabetes - Provided are methods, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes by administration of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues to a subject, where the microtissues comprise adipose stem cells and endothelial cells. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3D cell aggregates. | 2015-07-23 |
20150202235 | Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 2015-07-23 |
20150202236 | TOPICAL HALOBACTERIA EXTRACT COMPOSITION FOR TREATING RADIATION SKIN TISSUE DAMAGE - A composition for treating skin damage that includes halobacteria extracts and | 2015-07-23 |
20150202237 | HALOBACTERIA EXTRACTS COMPOSITION FOR TUMOR REDUCTION - A composition and method for treating solid tumors in a mammalian subject. The composition includes halobacterial extracts and | 2015-07-23 |
20150202238 | COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE - Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD. | 2015-07-23 |
20150202239 | COMPOSITIONS FOR A MEDICAL DEVICE COMPRISING EXOPOLYSACCHARIDE-PRODUCING BACTERIAL STRAINS IN ASSOCIATION WITH GUMS AND/OR GELATINES - A composition for a medical device is described. The composition comprises a specific mucoadherent gelling complex composed of EPS, exopolysaccharides of bacterial origin produced in situ in the gastrointestinal tract by specific selected bacterial strains, in association with vegetable gums and/or animal and/or vegetable gelatines. The complex is capable of establishing a complete barrier effect of a mechanical type extending throughout the whole gastrointestinal tract and can be used as a medication for the prevention and treatment of all pathologies connected to a deficiency in the barrier effect in the gastrointestinal area due to a low production of mucus, such as, by way of non-exhaustive example, intestinal permeability and bacterial translocation. | 2015-07-23 |
20150202240 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY - Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided. | 2015-07-23 |
20150202241 | USE FOR DENDROPANAX MORBIFERA EXTRACT FOR ADJUSTING 15- HYDROXYPROSTAGLANDIN DEHYDROGENASE AND PGE 2 ACTIVITY - Provided is a 15-PGDH activity adjusting function of a | 2015-07-23 |
20150202242 | HERBAL EXTRACT AND METHOD OF INHIBITING FAT-STORAGE FUNCTION OF ADIPOCYTES - The present invention discloses an herbal extract of inhibiting fat-storage function of adipocytes. The herbal extract comprises an | 2015-07-23 |
20150202243 | HDC Activation Inhibitor, HDC Activation Inhibition Composition, Antipruritic Agent, and Antipruritic Agent Composition - Provided are an HDC activation inhibitor and an antipruritic agent which are effective in animals against the itch caused by a itch generation mechanism different from the well-known one. | 2015-07-23 |